Takeda has launched ORZEYFUL™ (oveporexton) CIV in the United States. The company announced that adults with narcolepsy type 1 (NT1, narcolepsy with cataplexy) can now get the medicine by prescription. Moreover, ORZEYFUL brings the first and only orexin agonist to the narcolepsy type 1 community. Patients can learn more at ORZEYFUL.com.
Emily P., a clinical trial participant with NT1, shared what daily life with the condition looks like.
“Living with narcolepsy type 1 is an ongoing struggle to keep it together – from scheduling naps and anticipating sleep attacks to figuring out how to be present as a mom and a professional,” said Emily P., clinical trial participant with NT1. “With ORZEYFUL, I feel more confident planning my day because my narcolepsy has become more manageable.”
A New Approach to Narcolepsy Type 1 Treatment
Orexin deficiency drives NT1. As a result, the persistent 24-hour nature of the disease affects far more than daytime sleepiness. It shapes how people plan their days and navigate many parts of their lives. Tasks that others complete without thinking can require careful planning, endless calculations and constant balancing. Now, for the first time, people living with NT1 have a new option. This treatment targets the underlying orexin deficiency. Therefore, it treats the disease holistically rather than individual symptoms.
Physicians also welcome the launch. Dr. Emmanuel Mignot, M.D., Ph.D., served as principal U.S. investigator in the ORZEYFUL Phase 3 program.
“Clinical trials showed ORZEYFUL improved the full range of symptoms, and now we can bring those results into real-world practice,” said Dr. Emmanuel Mignot, M.D., Ph.D., principal U.S. investigator in the ORZEYFUL Phase 3 program. “Using ORZEYFUL to target the underlying cause of narcolepsy type 1 is a welcome and exciting development in sleep medicine. I can now start a new conversation with my patients about their symptoms and how using this new treatment approach may make a real difference for them.”
Takeda leaders also see the launch as a milestone.
“We work for decades toward the defining moments that have the potential to make a real difference for patients,” said Rhonda Pacheco, president of Takeda’s U.S. Business Unit. “Bringing ORZEYFUL, a first-in-class medicine, to people living with narcolepsy type 1 in the U.S. is one of those moments. We’re incredibly proud to be here, and equally focused on what comes next: supporting care and access for patients prescribed ORZEYFUL.”
How Patients Can Access ORZEYFUL
Licensed healthcare providers can prescribe ORZEYFUL. Accredo Specialty Pharmacy, part of Evernorth Health Services, will dispense it across the U.S. In addition, Takeda offers patient support programs for eligible adults who receive a prescription. These programs help patients get started. They also explain coverage steps and connect patients to available assistance options. For prescribing information and patient support details, visit ORZEYFUL.com.
About Narcolepsy Type 1, an Underdiagnosed Neurological Disease
NT1 is a rare, chronic neurological disease that stems from a loss of orexin. It affects an estimated 3 million people worldwide and 120,000 in the U.S. Patients experience excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), cognitive symptoms and disrupted nighttime sleep. Consequently, the disease can severely impact work, education and social relationships.
More than half of treated NT1 patients remain symptomatic. Furthermore, NT1 remains significantly underdiagnosed. Only an estimated 50% of patients receive a diagnosis in the U.S., and the process can take an average of 10 years. Symptom overlap with other sleep-wake and comorbidity disorders partly explains this gap. Limited availability of easy-to-use diagnostic tools adds to the problem. Takeda is working to potentially address these challenges. The company is developing biomarker solutions and digital tools that support earlier identification and differentiation of NT1.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com